168 related articles for article (PubMed ID: 30967101)
1. Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.
Brown TK; Noller GE; Denenberg JO
J Psychoactive Drugs; 2019; 51(2):155-165. PubMed ID: 30967101
[TBL] [Abstract][Full Text] [Related]
2. Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.
Malcolm BJ; Polanco M; Barsuglia JP
J Psychoactive Drugs; 2018; 50(3):256-265. PubMed ID: 29608409
[TBL] [Abstract][Full Text] [Related]
3. A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification.
Davis AK; Renn E; Windham-Herman AM; Polanco M; Barsuglia JP
J Psychoactive Drugs; 2018; 50(4):287-297. PubMed ID: 30020025
[TBL] [Abstract][Full Text] [Related]
4. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.
Noller GE; Frampton CM; Yazar-Klosinski B
Am J Drug Alcohol Abuse; 2018; 44(1):37-46. PubMed ID: 28402682
[TBL] [Abstract][Full Text] [Related]
5. Ibogaine in the treatment of substance dependence.
Brown TK
Curr Drug Abuse Rev; 2013 Mar; 6(1):3-16. PubMed ID: 23627782
[TBL] [Abstract][Full Text] [Related]
6. Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.
Cloutier-Gill L; Wood E; Millar T; Ferris C; Eugenia Socias M
J Psychoactive Drugs; 2016; 48(3):214-7. PubMed ID: 27192438
[TBL] [Abstract][Full Text] [Related]
7. Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence.
Knuijver T; Belgers M; Markus W; Verkes RJ; van Oosteren T; Schellekens A
J Clin Psychopharmacol; 2018 Dec; 38(6):646-648. PubMed ID: 30300292
[No Abstract] [Full Text] [Related]
8. [Ibogaine--the substance for treatment of toxicomania. Neurochemical and pharmacological action].
Kazlauskas S; Kontrimaviciūte V; Sveikata A
Medicina (Kaunas); 2004; 40(3):216-9. PubMed ID: 15064541
[TBL] [Abstract][Full Text] [Related]
9. DARK Classics in Chemical Neuroscience: Ibogaine.
Wasko MJ; Witt-Enderby PA; Surratt CK
ACS Chem Neurosci; 2018 Oct; 9(10):2475-2483. PubMed ID: 30216039
[TBL] [Abstract][Full Text] [Related]
10. Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.
Cherian K; Shinozuka K; Tabaac BJ; Arenas A; Beutler BD; Evans VD; Fasano C; Muir OS
Am J Ther; 2024 Mar-Apr 01; 31(2):e133-e140. PubMed ID: 38518270
[TBL] [Abstract][Full Text] [Related]
11. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.
Brown TK; Alper K
Am J Drug Alcohol Abuse; 2018; 44(1):24-36. PubMed ID: 28541119
[TBL] [Abstract][Full Text] [Related]
12. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats.
Glick SD; Kuehne ME; Maisonneuve IM; Bandarage UK; Molinari HH
Brain Res; 1996 May; 719(1-2):29-35. PubMed ID: 8782860
[TBL] [Abstract][Full Text] [Related]
13. How toxic is ibogaine?
Litjens RP; Brunt TM
Clin Toxicol (Phila); 2016; 54(4):297-302. PubMed ID: 26807959
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute opioid withdrawal with ibogaine.
Alper KR; Lotsof HS; Frenken GM; Luciano DJ; Bastiaans J
Am J Addict; 1999; 8(3):234-42. PubMed ID: 10506904
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse.
Luz M; Mash DC
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1019-1022. PubMed ID: 34139922
[No Abstract] [Full Text] [Related]
16. Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences.
Heink A; Katsikas S; Lange-Altman T
J Psychoactive Drugs; 2017; 49(3):201-208. PubMed ID: 28266890
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice.
Sunder Sharma S; Bhargava HN
Pharmacology; 1998 Nov; 57(5):229-32. PubMed ID: 9742287
[TBL] [Abstract][Full Text] [Related]
18. Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.
Wei D; Maisonneuve IM; Kuehne ME; Glick SD
Brain Res; 1998 Aug; 800(2):260-8. PubMed ID: 9685673
[TBL] [Abstract][Full Text] [Related]
19. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
Barsuglia JP; Polanco M; Palmer R; Malcolm BJ; Kelmendi B; Calvey T
Prog Brain Res; 2018; 242():121-158. PubMed ID: 30471678
[TBL] [Abstract][Full Text] [Related]
20. Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats.
Rho B; Glick SD
Neuroreport; 1998 May; 9(7):1283-5. PubMed ID: 9631413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
